![Hanne Callewaert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Hanne Callewaert was the founder of AstriVax NV and held the title of Chief Executive Officer.
Actieve functies van Hanne Callewaert
Bedrijven | Functie | Begin |
---|---|---|
AstriVax NV
![]() AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Algemeen Directeur | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
AstriVax NV
![]() AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Health Technology |